How India Exports Diphenhydramine to the World

Diphenhydramine, a first-generation antihistamine, is widely utilized in the United States for its sedative and anti-allergic properties. The U.S. Food and Drug Administration (FDA) has approved numerous Abbreviated New Drug Applications (ANDAs) for diphenhydramine products, indicating a well-established generic market. While specific approval dates for recent ANDAs are not detailed in the available sources, the FDA's Orange Book provides comprehensive listings of approved drug products, including diphenhydramine formulations.

Importantly, as of March 2026, there are no active FDA import alerts specifically targeting diphenhydramine products from India. This absence suggests that Indian manufacturers exporting diphenhydramine to the U.S. are generally in compliance with FDA regulations. However, it's crucial for exporters to remain vigilant, as the FDA can impose import alerts if products are found to violate regulatory standards. For instance, the FDA issues import alerts to protect consumers against products with a history of known violations, allowing for detention without physical examination (DWPE) of such products.

Given that 63.9% of India's diphenhydramine exports are destined for the United States, it is imperative for Indian exporters to adhere strictly to FDA requirements. This includes ensuring compliance with Good Manufacturing Practices (GMP), accurate labeling, and prompt reporting of any adverse events. Maintaining compliance not only facilitates uninterrupted market access but also upholds the reputation of Indian pharmaceutical products in the U.S. market.

In the European Union (EU) and the United Kingdom (UK), diphenhydramine is regulated as an over-the-counter (OTC) medicine for the treatment of allergies and insomnia. Marketing authorizations are granted by national regulatory agencies or, for centralized procedures, by the European Medicines Agency (EMA). Manufacturers must comply with the EU's Good Manufacturing Practice (GMP) guidelines, which ensure that products are consistently produced and controlled according to quality standards. These guidelines are detailed in EudraLex Volume 4.

Notably, in January 2010, Wyeth Consumer Healthcare withdrew its application for a marketing authorization for a combination product containing ibuprofen and diphenhydramine hydrochloride. The withdrawal was based on the Committee for Medicinal Products for Human Use's (CHMP) view that the data provided did not allow for a positive benefit-risk assessment (ema.europa.eu). This underscores the importance of robust clinical data and compliance with regulatory standards for successful market entry in the EU and UK.

Diphenhydramine is included in the World Health Organization's (WHO) Model List of Essential Medicines, recognizing its importance in a basic health system. The specific edition of the list should be consulted for the most current information. Inclusion in this list signifies the drug's critical role in addressing public health needs.

Regarding pharmacopoeial standards, diphenhydramine is monographed in major compendia, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). These monographs provide standardized specifications for the drug's quality, ensuring consistency and safety across different markets.

In India, diphenhydramine is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. This classification mandates that diphenhydramine can only be sold with a valid prescription from a registered medical practitioner.

The National Pharmaceutical Pricing Authority (NPPA) oversees the pricing of essential medicines in India. As of the latest available data, diphenhydramine is not listed under the Drugs (Prices Control) Order (DPCO), suggesting that it is not subject to price control regulations. However, manufacturers should regularly consult the NPPA for any updates to pricing policies.

For exporting diphenhydramine, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT). This certificate ensures that the export complies with national regulations and does not adversely affect domestic availability.

Diphenhydramine has been available for several decades, and its primary patents have long expired. This has led to a robust generic market with significant competition among manufacturers. The absence of active patents facilitates the production and export of diphenhydramine by multiple Indian pharmaceutical companies, contributing to the global supply of this essential medicine.

In September 2020, the FDA issued a Drug Safety Communication warning about serious problems associated with high doses of diphenhydramine. This alert was prompted by reports of teenagers participating in the "Benadryl Challenge" on social media, leading to hospitalizations and deaths. Manufacturers and exporters should be aware of such safety communications, as they can influence regulatory scrutiny and market demand.

As of March 2026, there have been no significant policy changes or new approvals related to diphenhydramine reported by major regulatory agencies such as the FDA, EMA, or India's CDSCO. However, the pharmaceutical industry is dynamic, and stakeholders should continuously monitor regulatory updates to ensure compliance and capitalize on market opportunities.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and intermediates, with China supplying approximately 70–80% of global KSMs and 60–70% of intermediates. This dependency exposes Indian manufacturers to supply chain vulnerabilities, particularly when Chinese production faces disruptions due to environmental regulations or geopolitical tensions.

For instance, in July 2018, environmental crackdowns in China led to the shutdown of several chemical plants, causing a ripple effect on global pharmaceutical supply chains. Indian API manufacturers experienced increased costs and supply shortages, highlighting the risks of over-reliance on a single source for critical raw materials.

The export market for Diphenhydramine from India is notably concentrated, with the top five exporters—ELYSIUM PHARMACEUTICALS LTD, MICRO LABS LIMITED, REAL DRUGS PRIVATE LIMITED, GRANULES INDIA LIMITED, and TRUECARE BIOMEDIX—accounting for 59.9% of total exports. ELYSIUM PHARMACEUTICALS LTD alone holds a 19.0% share, indicating a significant reliance on a limited number of suppliers.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in 2020, aiming to boost domestic API manufacturing and reduce dependence on imports. By 2025, the scheme had attracted investments exceeding ₹4,570 crore, fostering local production capabilities and enhancing supply chain resilience. (pharmanow.live)

Recent geopolitical events have further strained pharmaceutical supply chains. In February 2026, the closure of the Strait of Hormuz disrupted global shipping routes, delaying the transportation of pharmaceuticals and increasing costs. Approximately 20% of the world's oil passes through this strait, and its closure has had cascading effects on various industries, including pharmaceuticals.

Additionally, tensions in the Red Sea have led to rerouting of shipments, adding 10 to 14 days to transit times and escalating freight costs. These disruptions have caused delays in the delivery of essential medicines and increased operational expenses for pharmaceutical companies. (pharmasource.global)

To address these supply chain risks, the following strategies are recommended:

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different regions to reduce dependency on a single source.

• Enhance Domestic Production: Leverage government initiatives like the PLI scheme to strengthen local manufacturing capabilities for APIs and intermediates.

• Develop Alternative Shipping Routes: Establish contingency plans that include alternative logistics pathways to mitigate the impact of geopolitical disruptions.

• Increase Inventory Buffers: Maintain higher stock levels of critical raw materials and finished products to cushion against supply chain interruptions.

• Implement Robust Risk Monitoring: Utilize advanced analytics to continuously monitor geopolitical developments and supply chain vulnerabilities, enabling proactive risk management.

RISK_LEVEL: MEDIUM